190 related articles for article (PubMed ID: 17982413)
1. Safety of capecitabine use in patients with liver dysfunction.
Saif MW; Tejani MA
Clin Adv Hematol Oncol; 2007 Sep; 5(9):730-2; discussion 736. PubMed ID: 17982413
[No Abstract] [Full Text] [Related]
2. Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
Saadati H; Saif MW
JOP; 2008 May; 9(3):354-6. PubMed ID: 18469454
[No Abstract] [Full Text] [Related]
3. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
[TBL] [Abstract][Full Text] [Related]
4. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Saif MW; Diasio R
Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
[TBL] [Abstract][Full Text] [Related]
5. [Acute coronary syndrome during oral capecitabine monotherapy].
Martí V; Monell J; Seixo F; Falces C
Rev Esp Cardiol; 2008 May; 61(5):548-9. PubMed ID: 18462663
[No Abstract] [Full Text] [Related]
6. Fatal drug-drug interaction of brivudine and capecitabine.
Rätz Bravo AE; Hofer S; Krähenbühl S; Ludwig C
Acta Oncol; 2009; 48(4):631-3. PubMed ID: 19165642
[No Abstract] [Full Text] [Related]
7. Capecitabine cardiac toxicity presenting as effort angina: a case report.
Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
[TBL] [Abstract][Full Text] [Related]
8. Inflammation of actinic keratoses with capecitabine therapy for colon cancer.
Serrão VV; Feio AB
Eur J Dermatol; 2008; 18(2):200. PubMed ID: 18424393
[No Abstract] [Full Text] [Related]
9. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Seminara P; Losanno T; Emiliani A; Manna G
Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Videnovic A; Semenov I; Chua-Adajar R; Baddi L; Blumenthal DT; Beck AC; Simuni T; Futterer S; Gradishar W; Tellez C; Raizer JJ
Neurology; 2005 Dec; 65(11):1792-4; discussion 1685. PubMed ID: 16237130
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Schüll B; Scheithauer W; Kornek GV
Onkologie; 2003 Dec; 26(6):578-80. PubMed ID: 14709934
[TBL] [Abstract][Full Text] [Related]
12. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study.
Morganti AG; Picardi V; Ippolito E; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Caravatta L; Di Lullo L; Giglio G; Tambaro R; Mignogna S; Caprino P; Ingrosso M; Sofo L; Cellini N; Valentini V
Acta Oncol; 2010 May; 49(4):418-22. PubMed ID: 20397772
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
15. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
16. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
Saif MW; Black G; Johnson M; Russo S; Diasio R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):771-5. PubMed ID: 16552574
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Weger W; Kränke B; Gerger A; Salmhofer W; Aberer E
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S4-6. PubMed ID: 18625380
[TBL] [Abstract][Full Text] [Related]
18. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Xia Y; Qiu Y; Li J; Shi L; Wang K; Xi T; Shen F; Yan Z; Wu M
Ann Surg Oncol; 2010 Dec; 17(12):3137-44. PubMed ID: 20602260
[TBL] [Abstract][Full Text] [Related]
20. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
Villalón G; Martín JM; Pinazo MI; Calduch L; Alonso V; Jordá E
Am J Clin Dermatol; 2009; 10(4):261-3. PubMed ID: 19489659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
